| Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design JL Rokita, KS Rathi, MF Cardenas, KA Upton, J Jayaseelan, KL Cross, ... Cell reports 29 (6), 1675-1689. e9, 2019 | 152 | 2019 |
| The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models NM Kendsersky, J Lindsay, EA Kolb, MA Smith, BA Teicher, SW Erickson, ... Clinical Cancer Research 27 (10), 2938-2946, 2021 | 71 | 2021 |
| Epigenomic profiling of neuroblastoma cell lines K Upton, A Modi, K Patel, NM Kendsersky, KL Conkrite, RT Sussman, ... Scientific data 7 (1), 116, 2020 | 61 | 2020 |
| A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope S Raman, SN Buongervino, MV Lane, DV Zhelev, Z Zhu, H Cui, ... Cell Reports Medicine 2 (7), 2021 | 25* | 2021 |
| Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma M Makvandi, M Samanta, P Martorano, H Lee, SB Gitto, K Patel, D Groff, ... Communications Biology 5 (1), 1260, 2022 | 7 | 2022 |
| ROGUE: an R Shiny app for RNA sequencing analysis and biomarker discovery A Farrel, P Li, S Veenbergen, K Patel, JM Maris, WJ Leonard BMC bioinformatics 24 (1), 1-13, 2023 | 1 | 2023 |
| A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma HF Zhang, A Delaidelli, S Javed, B Turgu, T Morrison, CS Hughes, ... Science Advances 9 (34), eadg6693, 2023 | | 2023 |
| Discovering the genetic basis of neuroblastoma initiation and progression SJD Zalman Vaksman1 , Emily Blauel1 , Alex L. Lee1 , Laura E. Egolf1 ... https://commonfund.nih.gov/sites/default/files …, 2019 | | 2019 |
